Wedbush Analysts Boost Earnings Estimates for AnaptysBio

3 days ago · Wedbush analyst D. Nierengarten now forecasts that the biotechnology company will post earnings per share of ($0.44) for the quarter, up from their prior forecast of ($0.96). …

CouponFollow Extension

$0.44
OFF

Wedbush Analysts Boost Earnings Estimates For AnaptysBio

2 weeks from now

3 days ago · Wedbush analyst D. Nierengarten now forecasts that the biotechnology company will post earnings per share of ($0.44) for the quarter, up from their prior forecast of ($0.96). …

marketbeat.com

$4.04
OFF

FY2029 Earnings Estimate For AnaptysBio Issued By Wedbush

2 weeks from now

3 days ago · Wedbush analyst D. Nierengarten expects that the biotechnology company will earn ($4.04) per share for the year. Wedbush has a "Outperform" rating and a $40.00 price target …

marketbeat.com

$1.14
OFF

AnaptysBio (ANAB) Earnings Date And Reports 2025 - MarketBeat

2 weeks from now

Jan 31, 2025 · AnaptysBio released Q3 2024 earnings on November 5, 2024, reporting an EPS of -$1.14, which topped the consensus estimate of -$1.72 by $0.58. Quarterly revenue was …

marketbeat.com

$42.00
OFF

AnaptysBio’s (ANAB) Outperform Rating Reiterated At Wedbush

2 weeks from now

Nov 9, 2024 · Wedbush currently has a $42.00 target price on the biotechnology company’s stock. Wedbush also issued estimates for AnaptysBio’s Q4 2024 earnings at ($0.81) EPS, FY2024 …

etfdailynews.com

$1.62
OFF

AnaptysBio, Inc. To Post Q3 2024 Earnings Of ($1.62) Per Share, …

2 weeks from now

Aug 10, 2024 · AnaptysBio, Inc. (NASDAQ:ANAB – Free Report) – Investment analysts at Wedbush increased their Q3 2024 EPS estimates for AnaptysBio in a research note issued to …

mayfieldrecorder.com

$40.00
OFF

Wedbush Sticks To Its Buy Rating For AnaptysBio (ANAB)

2 weeks from now

16 hours ago · Wedbush analyst David Nierengarten maintained a Buy rating on AnaptysBio (ANAB – Research Report) today and set a price target of $40.00. The company’s shares …

businessinsider.com

$36.17
OFF

Analyst Expectations For AnaptysBio's Future - Nasdaq

2 weeks from now

3 days ago · Analysts have recently evaluated AnaptysBio and provided 12-month price targets. The average target is $36.17, accompanied by a high estimate of $66.00 and a low estimate of …

nasdaq.com

$100
OFF

Strategic Upward Striving Toward $100 Million Revenue: …

2 weeks from now

tional investors, analyst following, media coverage, and CEO bonuses and share-based compensation. Third, shooting range firms increase acquisitions, hiring of employees, and …

columbia.edu

$1.60
OFF

AnaptysBio’s (ANAB) “Outperform” Rating Reaffirmed At Wedbush

2 weeks from now

May 14, 2024 · Wedbush also issued estimates for AnaptysBio’s Q1 2025 earnings at ($1.60) EPS, Q2 2025 earnings at ($1.63) EPS and […] Skip to main content Analyst Ratings

etfdailynews.com

$1.14
OFF

AnaptysBio (NASDAQ:ANAB) Upgraded To "Strong-Buy" At Wolfe …

2 weeks from now

3 days ago · The biotechnology company reported ($1.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.72) by $0.58. The business had revenue of …

marketbeat.com

$1.14
OFF

AnaptysBio (NASDAQ:ANAB) Receives "Outperform" Rating From …

2 weeks from now

4 days ago · AnaptysBio (NASDAQ:ANAB - Get Free Report) last posted its earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) EPS for the quarter, …

marketbeat.com

$1.14
OFF

AnaptysBio (NASDAQ:ANAB) Shares Gap Up - Should You Buy?

2 weeks from now

4 days ago · The biotechnology company reported ($1.14) earnings per share for the quarter, beating analysts' consensus estimates of ($1.72) by $0.58. AnaptysBio had a negative return …

marketbeat.com

FAQs about Wedbush Analysts Boost Earnings Estimates for AnaptysBio Coupon?

Did Wedbush raise earnings estimates for anaptysbio (Anab) in Q1 2025?

AnaptysBio, Inc. (NASDAQ:ANAB – Free Report) – Equities research analysts at Wedbush lifted their Q1 2025 earnings estimates for AnaptysBio in a research note issued on Monday, February 3rd. ...

Should you buy Wedbush (anaptysbio) stock?

Wedbush currently has a “Outperform” rating and a $40.00 price target on the stock. The consensus estimate for AnaptysBio’s current full-year earnings is ($6.08) per share. ...

How much will anaptysbio (Anab) earn in Q2 2025?

Wedbush also issued estimates for AnaptysBio’s Q2 2025 earnings at ($0.85) EPS, Q3 2025 earnings at ($0.87) EPS, Q4 2025 earnings at ($0.89) EPS, FY2025 earnings at ($3.05) EPS, FY2026 earnings at ($3.75) EPS, FY2027 earnings at ($4.13) EPS and FY2028 earnings at ($4.77) EPS. A number of other research analysts also recently commented on ANAB. ...

What will anaptysbio's earnings look like in 2024?

Following the latest upgrade, the current consensus, from the nine analysts covering AnaptysBio, is for revenues of US$15m in 2024, which would reflect a chunky 11% reduction in AnaptysBio's sales over the past 12 months. Per-share losses are expected to creep up to US$6.26. ...

Should you buy anaptysbio (Anab) stock?

AnaptysBio (NASDAQ:ANAB – Get Free Report)‘s stock had its “outperform” rating reaffirmed by equities researchers at Wedbush in a research note issued to investors on Monday,RTT News reports. They currently have a $40.00 price target on the biotechnology company’s stock. ...

How much did anaptysbio IPO cost?

AnaptysBio (ANAB) raised $60 million in an initial public offering (IPO) on Thursday, January 26th 2017. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Credit Suisse and Stifel acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. Who are AnaptysBio's major shareholders? ...